Hydroxychloroquine trial inconclusiveA clinical study on a preventive virus treatment using hydroxychloroquine, a controversial drug that has been touted as a possible cure for the novel coronavirus, was inconclusive, according to the Korean researchers.
Researchers from Samsung Medical Center in southern Seoul and Pusan National University Hospital in Busan completed post-exposure prophylaxis (PEP) using hydroxychloroquine (HCQ) on 184 patients and 21 health care workers at a long-term care hospital in Busan, where they were exposed to the coronavirus after massive infections were reported there.
Post-exposure prophylaxis refers to any preventive medical treatment started after exposure to a pathogen. HCQ is an anti-malaria drug that recently gained worldwide attention after U.S. President Donald Trump said it could be a cure for Covid-19, although medical experts are divided over the use of the drug, citing side effects.
According to the study, which was published in the International Journal of Antimicrobial Agents, Korean researchers conducted the treatment on people who were at risk of contracting Covid-19, although their baseline polymerase chain reaction tests for the novel coronavirus were negative.
Researchers gave the subjects a daily dose of 400 milligrams of HCQ until the completion of a 14-day quarantine period. During the trial, 32 people reported one or more symptoms, including diarrhea, skin rash and gastrointestinal problems, the study showed.
At the end of 14 days of quarantine, follow-up tests on the study participants were all negative, indicating that those who received the treatment did not develop Covid-19.
However, researchers said that this does not mean the post-exposure treatment is “effective for the prevention of Covid-19,” as there was no adequate control group.
“Although there was no adequate control group and it was conducted at a single center, this is the first study to use PEP with HCQ as an outbreak response against Covid-19 in a [long-term care hospital],” they said. “Randomized clinical studies are needed to evaluate if PEP is an effective option for outbreak response against Covid-19 in [long-term care hospitals].”
Some medical experts here criticized the study, saying it was too hasty a move to test HCQ on patients at high risk, as the drug is not even used in the United States and Europe as a Covid-19 treatment yet.
More in Industry
Sale of Doosan Infracore stake could be opportunity for Hyundai Heavy
Volvo XC60 ranks No. 1 for residual value in Encar study
Binggrae to scoop up ice cream competitor after FTC approves merger
LG accepting orders for rollable, $85K television
Shinsegae Group chair passes down shares to children